C4 Therapeutics (CCCC)
(Delayed Data from NSDQ)
$3.16 USD
-0.16 (-4.82%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $3.23 +0.07 (2.22%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth D Momentum F VGM
Fundamental Charts
About Dividend Yield (TTM)
C4 Therapeutics, Inc.'s dividend yield currently sits at 0%, which is in-line with the Medical - Biomedical and Genetics industry's yield of 0.00%.
The company's trailing twelve month (TTM) Dividend Yield calculates the indicated annual dividend divided by the stock price. This value is always expressed as a percentage. This is the return on investment that is specifically attributed to the expected dividends that are paid out over a year. Note: investors should not base their investments on the size of the dividend yield alone. Seek attractive dividend yields, but only on top rated stocks with a solid payment history.
CCCC 3.16 -0.16(-4.82%)
Will CCCC be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for CCCC based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for CCCC
C4 Therapeutics, Inc. (CCCC) Reports Q2 Loss, Misses Revenue Estimates
Ocugen (OCGN) Reports Q2 Loss, Misses Revenue Estimates
CCCC: What are Zacks experts saying now?
Zacks Private Portfolio Services
C4 Therapeutics, Inc. (CCCC) Reports Q1 Loss, Tops Revenue Estimates
Sage Therapeutics, Inc. (SAGE) Reports Q1 Loss, Misses Revenue Estimates
C4 Therapeutics (CCCC) Loses -21.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Other News for CCCC
Golden Cross appears for CCCC after 1.78% move
Upper Bollinger Band Walk appears for CCCC after 0.88% move
CCCC forms Jack-in-the-box Bullish on September 16
Analyst Barclays Initiates Coverage on C4 Therapeutics (CCCC) with Overweight Rating | CCCC ...
Oncology Investment Surge Hits $1.3B as Private Sector Fills Public Funding Gaps